文献速递癫痫认知障碍与痴呆

阿杜那单抗诱导的淀粉样蛋白相关影像学异常患者中的难治性癫痫持续状态

Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities.
PubMed 文献 · Neurology · 2024-08-09

报告一例与淀粉样蛋白相关影像学异常(ARIA)相关的致死性超级难治性癫痫持续状态。患者为75岁阿尔茨海默病所致轻度认知障碍女性(载脂蛋白ε4纯合子),有3次无症状ARIA发作史,参与阿杜那单抗开放标签扩展试验,因左侧额叶和枕叶两个非连续区域局灶性癫痫发作和ARIA入院,尽管接受大剂量皮质类固醇、镇静和抗癫痫药物治疗,仍死于难治性局灶性癫痫持续状态。回顾性分析发现,住院前11周的常规监测脑MRI已有ARIA征象但未被识别。

要点

  • 抗淀粉样蛋白治疗可能导致罕见严重不良事件,临床医生应知晓。
  • 解读ARIA监测影像时需要高度警惕。
  • 纵向研究有助于进一步明确抗淀粉样蛋白抗体治疗的安全性特征并识别严重不良事件高危参与者。

核心结论

  • 临床医生应知晓抗淀粉样蛋白治疗可能导致罕见严重不良事件,解读ARIA监测影像需高度警惕,纵向研究有助于进一步明确抗淀粉样蛋白抗体治疗的安全性特征并识别严重不良事件高危参与者。

研究设计与样本

  • 病例报告:描述一名75岁阿尔茨海默病所致轻度认知障碍患者(载脂蛋白ε4纯合子)的病史、神经影像、脑电图和脑病理学发现。

主要发现

  • 患者有3次无症状ARIA发作史,参与阿杜那单抗开放标签扩展试验,因左侧额叶和枕叶两个非连续区域局灶性癫痫发作和ARIA入院。
  • 尽管接受大剂量皮质类固醇、镇静和抗癫痫药物治疗,患者仍死于难治性局灶性癫痫持续状态。
  • 回顾性分析发现,住院前11周的常规监测脑MRI已有ARIA征象但未被识别。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report a case of fatal super-refractory status epilepticus associated with amyloid-related imaging abnormalities (ARIA). METHODS: We describe the history, neuroimaging, EEG, and brain pathology findings of a 75-year-old patient with mild cognitive impairment due to Alzheimer disease (homozygous ε4 apolipoprotein status) and a remote history of 3 asymptomatic ARIA episodes, who developed super-refractory status epilepticus related to severe ARIA. RESULTS: The patient was participating in an extended open-label trial of aducanumab when she was admitted to hospital for focal seizures and ARIA in 2 noncontiguous regions of the left frontal and occipital lobes. Despite aggressive treatment with high-dose corticosteroids, sedation, and antiseizure medications, she died from refractory focal status epilepticus. In retrospect, routine surveillance brain magnetic resonance imaging performed 11 weeks before hospitalization had signs of ARIA, which had not been identified. DISCUSSION: Clinicians should be aware that anti-amyloid therapies may cause rare serious adverse events. A high degree of vigilance is required in the interpretation of surveillance imaging for ARIA. Longitudinal studies are justified to further characterize the safety profile of anti-amyloid antibody therapies and identify participants at high risk of serious adverse events.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Neves Briard J, Duquette A, Cayrol R, et al. Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities. Neurology. 2024. PMID: 39121445. doi:10.1212/WNL.0000000000209582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。